Coronavirus Disease 2019 (COVID-19) is an acute respiratory disease caused by novel coronavirus SARS-CoV-2. Cancer patients may be at higher risk for developing severe COVID-19; significant risk factors for severity and mortality of COVID-19 in cancer patients.

Any solid tumors (lung cancer, pancreatic cancer) as well as hematological malignancies (leukemias) may require prompt diagnosis and treatment based on the disease aggression and progression. The coronavirus SARS-CoV-2 (COVID-19) outbreak is having a profound impact on the management of patients with cancer. We are obtaining more knowledge on the COVID-19 pandemic consequences that are currently impacting and may continue to further challenge cancer care in several countries.

Issues pertaining to the risk of COVID-19 in patients with cancer, clinical presentation in patients with malignancy, and the approach to testing in cancer patients are discussed separately as are the management of COVID-19 in the general population and issues related to particular patient populations.

Journal of carcinogenesis & Mutagenesis is using Editorial Tracking System for quality in review process. Editorial Tracking is an online manuscript submission, review and tracking systems used by most of the best open access journals.

Review processing is performed by the editorial board members of carcinogenesis & Mutagenesis (Volume 11) or outside experts; at least two independent reviewers approval followed by editor's approval is required for acceptance of any citable manuscript.

Authors are requested to submit their manuscripts as an e-mail attachment to mail

Our journal shares all the views and ideas about Cancer. If u has anything related to cancer patients during this COVID-19 pandemic era which will provide an awareness to several cancer patients, you can contact us.

Caring for those with cancer in the times of Covid-19.

Best regards
Editorial Team
Journal of Carcinogenesis & Mutagenesis
NLM ID: 10161210